In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

High triglycerides, low HDL cholesterol and a low LDL cholesterol per apolipoprotein B ratio predict incident diabetes in patients with established coronary artery disease

Session Poster session 5

Speaker Christoph Saely

Event : ESC Congress 2015

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease and Comorbidities
  • Session type : Poster Session

Authors : CH Saely (Feldkirch,AT), P Rein (Feldkirch,AT), A Vonbank (Feldkirch,AT), D Zanolin (Triesen,LI), G Naerr (Triesen,LI), A Leiherer (Feldkirch,AT), A Muendlein (Feldkirch,AT), H Drexel (Philadelphia,US)

Authors:
C.H. Saely1 , P. Rein1 , A. Vonbank1 , D. Zanolin2 , G. Naerr2 , A. Leiherer3 , A. Muendlein3 , H. Drexel4 , 1Academic Teaching Hospital, Department of Medicine and Cardiology - Feldkirch - Austria , 2Private University of the Principality of Liechtenstein - Triesen - Liechtenstein , 3VIVIT Institute - Feldkirch - Austria , 4Drexel University College of Medicine - Philadelphia - United States of America ,

Citation:
European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 764

Background and introduction: Patients with type 2 diabetes mellitus (T2DM) exhibit a typical pattern of dyslipidemia with low HDL cholesterol, high triglycerides and a low LDL cholesterol per apolipoprotein B (LDL-C/apoB) ratio reflecting small LDL particles.

Purpose: The purpose of our study was to test the hypothesis that high triglycerides, low HDL cholesterol and a low LDL-C/apoB ratio predict incident T2DM among non-diabetic patients with established coronary artery disease (CAD).

Methods: We enrolled 655 non-diabetic patients with angiographically proven stable CAD. Prospectively, the incidence of T2DM was recorded over a mean follow-up period of 6.1±3.7 years. Diabetes was diagnosed according to ADA criteria.

Results: From our non-diabetic coronary patients, 358 (54.7%) at baseline had normal fasting glucose (NFG) <100 mg/dl, and 297 (45.3%) had impaired fasting glucose (IFG) ≥100 mg/dl. During follow-up, T2DM was newly diagnosed in 17.4% of our patients. Baseline IFG compared to NFG was associated with a strongly increased risk of T2DM (26.6% vs. 9.8%; adjusted OR 3.34 [2.17–5.16]; p<0.001). Low HDL cholesterol, high triglycerides, and a low LDL-C/apoB ratio after multivariate adjustment including fasting glucose significantly predicted incident diabetes in the total study cohort (OR 0.65 [0.49–0.86]; p=0.003, 1.40 [1.13–1.74]; p=0.002 and 0.54 [0.41–0.71]; p<0.001, respectively) and also when we separately analyzed patients with IFG (OR 0.67 [0.46–0.97]; p=0.032, 1.42 [1.03–1.96]; p=0.032 and 0.56 [0.39–0.79]; p=0.001, respectively) and NFG (OR 0.62 [0.40–0.96]; p=0.034, 1.38 [1.03–1.86]; p=0.033 and 0.49 [0.32–0.76]; p=0.001, respectively).

Conclusion: We conclude that among patients with angiographically proven stable CAD the incidence of diabetes is high, particularly among those with IFG. Importantly, high triglycerides, low HDL cholesterol and a low LDL-C/apoB ratio significantly predict incident diabetes independently from baseline glycemia.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are